New research shows individuals with a greater degree of activity in the stress center of the brain also have more evidence of inflammation in their arteries and were at higher risk for cardiovascular events, including heart attack, stroke and death.

April 5, 2016 — Philips announced that a combined total of more than 5,000 patients have been enrolled in three prospective clinical studies to assess Philips Volcano’s proprietary iFR (instant wave-Free Ratio) measurement technology.

Chest pain and shortness of breath are the most common symptoms reported by both women and men with suspected heart disease, a finding in contrast to prior data.

Novel technology developed by HeartFlow Inc. significantly reduces the need for invasive procedures to diagnose patients suspected of having coronary artery disease.

There has been a lot of conjecture that transcatheter aortic valve replacement (TAVR) may one day replace open-heart surgical aortic valve replacement (SAVR). However, after attending the American College of Cardiology (ACC) 2016 meeting, it is evident that change will come much sooner than anyone anticipated. “Wow” is really the key summary I can offer regarding the TAVR vs. SAVR data presented at ACC. Three key presentations were all positive for TAVR, showing it is at least equal or superior to surgery.

Many patients who have an implantable cardioverter defibrillator (ICD) are unaware the device can be deactivated to prevent painful shocks in their final days of life, according to two new studies.

Partner 2A, Partner IIa, TAVR vs. surgery

April 2, 2016 — Intermediate-risk patients with severe aortic stenosis who receive minimally invasive transcatheter aortic valve replacement (TAVR) have similar rates of death and disabling strokes after two years compared to open heart surgery, according to a new study. The study was presented at the American College of Cardiology’s 65th Annual Scientific Session. Patients receiving TAVR also experienced shorter hospital stays and lower incidence of some major complications compared with those undergoing surgery. 

AstraZeneca confirmed that the American College of Cardiology (ACC) and American Heart Association (AHA) have released a treatment guideline on the duration of dual antiplatelet therapy (DAPT).

Although nearly three-quarters of women taking a recent survey had one or more risk factors for heart disease, just 16 percent had actually been told by their doctors that these factors put them at risk for heart disease.

Siemens will unveil a revamped version of its established Sensis hemodynamic system at the 65 th Annual Scientific Session and Expo of the American College of Cardiology (ACC), April 2-4 in Chicago.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now